FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

Andrea Botticelli; Federica Mazzuca; Marina Borro; Eva Mazzotti; Marco La Torre; Adriana Bonifacino; Francesca Romana Ciabatta; Giovanna Gentile; Chiara Maddalena; Maurizio Simmaco; Paolo Marchetti

doi:10.14740/wjon934w

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.

Affiliations

¹ Department of Molecular and Clinical Medicine, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
² Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome - Advanced Molecular Diagnostics Unit (DiMA), Sant'Andrea Hospital, Rome, Italy.
³ Department of General Surgery, Sant'Andrea Hospital, Rome, Italy.

Abstract

Background: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients.

Methods: Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed.

Results: No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012).

Conclusions: Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy.

Keywords: Breast cancer; FCGR; Polymorphisms; Trastuzumab.